Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE versus LIDOCAINE HYDROCHLORIDE 0 1 AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE versus LIDOCAINE HYDROCHLORIDE 0 1 AND DEXTROSE 5 IN PLASTIC CONTAINER.
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE vs LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine blocks voltage-gated sodium channels on neuronal membranes, inhibiting the propagation of action potentials and resulting in local anesthesia.
Lidocaine is a sodium channel blocker, which stabilizes neuronal membranes and inhibits the initiation and conduction of nerve impulses. Dextrose 5% provides caloric support.
0.25-0.5% solution, up to 2 mg/kg (max 150 mg) per dose via infiltration, peripheral nerve block, or epidural; may repeat every 3-6 hours as needed. For epidural: 0.5% solution, 15-20 mL for surgical anesthesia.
Intravenous: 50-100 mg bolus (1-2 mg/kg) over 2-3 minutes, followed by continuous infusion at 1-4 mg/min (20-50 mcg/kg/min). Total maximum dose: 300 mg over 1 hour.
None Documented
None Documented
Terminal elimination half-life is 2.7 hours (range 1.5-5.5 hours). Prolonged up to 8-10 hours in neonates and 24-48 hours in severe hepatic impairment.
Terminal elimination half-life: 1.5–2.0 hours in adults with normal hepatic function. In patients with hepatic impairment or heart failure, half-life may be prolonged (>3 hours). Clinical context: short half-life requires continuous infusion for sustained antiarrhythmic effect.
Renal excretion accounts for approximately 95% of the dose, with about 50% excreted unchanged. The remainder is primarily hepatic metabolism followed by renal elimination of metabolites. Biliary/fecal excretion is minimal (<5%).
Renal: approximately 10% unchanged; hepatic metabolism to 4-hydroxy-2,6-xylidine and glycylxylidide, which are excreted renally. Total renal excretion of metabolites and parent drug accounts for >95% of the dose. Fecal excretion is minimal (<5%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)